Enter a phrase above to search files and articles within the site.

Typically materials that are more than 5 years old will be archived

Make a Donation

https://www.niams.nih.gov/about/budget/make-donation

Anyone, an individual or an organization, can donate to the NIAMS. The NIAMS is federally funded and not a fundraising organization; but, the U.S. Congress authorizes NIAMS to accept donations and bequests to support the scientific mission of the Institute. Donations to NIAMS are deposited in a NIAMS “Gift Fund”

Subset Analysis in Clinical Studies Roundtable - March 11, 2020

https://www.niams.nih.gov/about/meetings-events/roundtables/subset-analysis-clinical-studies-roundtable-march-11-2020

See participant list See Backgrounder Summary Welcome (Bob Carter, 0:001) Dr. Carter provided an overview of why NIAMS was holding this meeting (see background), acknowledged key staff who were involved in its development, and urged participants to keep the discussions focused on the scientific needs and opportunities related to subset analysis in clinical studies. He asked everyone to think broadly about how the various statistical approaches could be applied to NIAMS mission areas and to share their contributions during the afternoon discussion. 1 Times are noted in approximate hours and minutes on the videocast. The link does not take the

Data and Safety Monitoring Boards—PI Responsibilities

https://www.niams.nih.gov/grants-funding/conducting-clinical-research/trial-policies-guidelines-templates/data-safety-monitoring-guidelines-policies/principal-investigator-responsibilities

The clinical study Principal Investigator (PI) safety monitoring responsibilities with respect to a Data and Safety Monitoring Board (DSMB) or Observational Study Monitoring Board (OSMB) ensure the study is conducted according to the highest scientific and ethical standards. Responsibilities are outlined in bold italics.

Osteoarthritis Initiative Application Guide for Biospecimen Studies

https://www.niams.nih.gov/grants-funding/funded-research/osteoarthritis-initiative/osteoarthritis-initiative-application

This document outlines the process by which requests for access to existing biospecimens from the OAI resource are processed, evaluated, and approved. Types of Specimen Available Type of Specimen Maximum Allowable Specimen Per Study Serum 0.15 ml (total of serum and plasma per study) EDTA plasma 0.15 ml (total of